The increased activity of a transcription factor inhibits autophagy in diabetic embryopathy.
Analysis of Variance
Animals
Autophagy
/ genetics
Diabetes Mellitus, Experimental
Diabetes, Gestational
/ genetics
Disease Models, Animal
Female
Fetal Diseases
/ genetics
Forkhead Box Protein O3
/ genetics
Gene Expression Regulation, Developmental
Mice
Neural Tube Defects
/ diagnostic imaging
Pregnancy
Pregnancy, Animal
Real-Time Polymerase Chain Reaction
/ methods
Sensitivity and Specificity
Transcription Factors
/ genetics
congenital anomalies
diabetic embryopathy
impaired autophagy
maternal diabetes
teratogenesis
Journal
American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
11
07
2018
revised:
28
09
2018
accepted:
01
10
2018
pubmed:
13
10
2018
medline:
19
10
2019
entrez:
13
10
2018
Statut:
ppublish
Résumé
Maternal diabetes induces neural tube defects and stimulates the activity of the forkhead box O3 (Fox)O3a in the embryonic neuroepithelium. We previously demonstrated that deleting the FOXO3a gene ameliorates maternal diabetes-induced neural tube defects. Macroautophagy (hereafter referred to as "autophagy") is essential for neurulation. Rescuing autophagy suppressed by maternal diabetes in the developing neuroepithelium inhibits neural tube defect formation in diabetic pregnancy. This evidence suggests a possible link between FoxO3a and impaired autophagy in diabetic embryopathy. We aimed to determine whether maternal diabetes suppresses autophagy through FoxO3a, and if the transcriptional activity of FoxO3a is required for the induction of diabetic embryopathy. We used a well-established type 1 diabetic embryopathy mouse model, in which diabetes was induced by streptozotocin, for our in vivo studies. To determine if FoxO3a mediates the inhibitory effect of maternal diabetes on autophagy in the developing neuroepithelium, we induced diabetic embryopathy in FOXO3a gene knockout mice and FoxO3a dominant negative transgenic mice. Embryos were harvested at embryonic day 8.5 to determine FoxO3a and autophagy activity and at embryonic day 10.5 for the presence of neural tube defects. We also examined the expression of autophagy-related genes. C17.2 neural stem cells were used for in vitro examination of the potential effects of FoxO3a on autophagy. Deletion of the FOXO3a gene restored the autophagy markers, lipidation of microtubule-associated protein 1A/1B-light chain 3I to light chain 3II, in neurulation stage embryos. Maternal diabetes decreased light chain 3I-positive puncta number in the neuroepithelium, which was restored by deleting FoxO3a. Maternal diabetes also decreased the expression of positive regulators of autophagy (Unc-51 like autophagy activating kinase 1, Coiled-coil myosin-like BCL2-interacting protein, and autophagy-related gene 5) and the negative regulator of autophagy, p62. FOXO3a gene deletion abrogated the dysregulation of autophagy genes. In vitro data showed that the constitutively active form of FoxO3a mimicked high glucose in repressing autophagy. In cells cultured under high-glucose conditions, overexpression of the dominant negative FoxO3a mutant blocked autophagy impairment. Dominant negative FoxO3a overexpression in the developing neuroepithelium restored autophagy and significantly reduced maternal diabetes-induced apoptosis and neural tube defects. Our study revealed that diabetes-induced FoxO3a activation inhibited autophagy in the embryonic neuroepithelium. We also observed that FoxO3a transcriptional activity mediated the teratogenic effect of maternal diabetes because dominant negative FoxO3a prevents maternal diabetes-induced autophagy impairment and neural tube defect formation. Our findings suggest that autophagy activators could be therapeutically effective in treating maternal diabetes-induced neural tube defects.
Sections du résumé
BACKGROUND
Maternal diabetes induces neural tube defects and stimulates the activity of the forkhead box O3 (Fox)O3a in the embryonic neuroepithelium. We previously demonstrated that deleting the FOXO3a gene ameliorates maternal diabetes-induced neural tube defects. Macroautophagy (hereafter referred to as "autophagy") is essential for neurulation. Rescuing autophagy suppressed by maternal diabetes in the developing neuroepithelium inhibits neural tube defect formation in diabetic pregnancy. This evidence suggests a possible link between FoxO3a and impaired autophagy in diabetic embryopathy.
OBJECTIVE
We aimed to determine whether maternal diabetes suppresses autophagy through FoxO3a, and if the transcriptional activity of FoxO3a is required for the induction of diabetic embryopathy.
STUDY DESIGN
We used a well-established type 1 diabetic embryopathy mouse model, in which diabetes was induced by streptozotocin, for our in vivo studies. To determine if FoxO3a mediates the inhibitory effect of maternal diabetes on autophagy in the developing neuroepithelium, we induced diabetic embryopathy in FOXO3a gene knockout mice and FoxO3a dominant negative transgenic mice. Embryos were harvested at embryonic day 8.5 to determine FoxO3a and autophagy activity and at embryonic day 10.5 for the presence of neural tube defects. We also examined the expression of autophagy-related genes. C17.2 neural stem cells were used for in vitro examination of the potential effects of FoxO3a on autophagy.
RESULTS
Deletion of the FOXO3a gene restored the autophagy markers, lipidation of microtubule-associated protein 1A/1B-light chain 3I to light chain 3II, in neurulation stage embryos. Maternal diabetes decreased light chain 3I-positive puncta number in the neuroepithelium, which was restored by deleting FoxO3a. Maternal diabetes also decreased the expression of positive regulators of autophagy (Unc-51 like autophagy activating kinase 1, Coiled-coil myosin-like BCL2-interacting protein, and autophagy-related gene 5) and the negative regulator of autophagy, p62. FOXO3a gene deletion abrogated the dysregulation of autophagy genes. In vitro data showed that the constitutively active form of FoxO3a mimicked high glucose in repressing autophagy. In cells cultured under high-glucose conditions, overexpression of the dominant negative FoxO3a mutant blocked autophagy impairment. Dominant negative FoxO3a overexpression in the developing neuroepithelium restored autophagy and significantly reduced maternal diabetes-induced apoptosis and neural tube defects.
CONCLUSION
Our study revealed that diabetes-induced FoxO3a activation inhibited autophagy in the embryonic neuroepithelium. We also observed that FoxO3a transcriptional activity mediated the teratogenic effect of maternal diabetes because dominant negative FoxO3a prevents maternal diabetes-induced autophagy impairment and neural tube defect formation. Our findings suggest that autophagy activators could be therapeutically effective in treating maternal diabetes-induced neural tube defects.
Identifiants
pubmed: 30312583
pii: S0002-9378(18)30870-6
doi: 10.1016/j.ajog.2018.10.001
pmc: PMC6463484
mid: NIHMS1012940
pii:
doi:
Substances chimiques
Forkhead Box Protein O3
0
FoxO3 protein, mouse
0
Transcription Factors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
108.e1-108.e12Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK101972
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118491
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL131737
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK103024
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL139060
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK083243
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL134368
Pays : United States
Informations de copyright
Copyright © 2018. Published by Elsevier Inc.
Références
Am J Obstet Gynecol. 2018 Jan;218(1):136.e1-136.e10
pubmed: 29100869
Sci Signal. 2013 Aug 27;6(290):ra74
pubmed: 23982205
Biochim Biophys Acta. 2011 Nov;1813(11):1978-86
pubmed: 21440011
Am J Obstet Gynecol. 2017 May;216(5):527.e1-527.e9
pubmed: 28043842
World J Diabetes. 2015 Apr 15;6(3):481-8
pubmed: 25897357
J Pharm Sci. 2011 Jun;100(6):2020-53
pubmed: 21337544
Toxicol Sci. 2017 Aug 1;158(2):275-285
pubmed: 28482072
Am J Physiol Endocrinol Metab. 2013 Sep 1;305(5):E667-78
pubmed: 23880312
Diabetes. 2012 Aug;61(8):2084-92
pubmed: 22688338
Am J Obstet Gynecol. 2018 Mar;218(3):345.e1-345.e30
pubmed: 29305255
Am J Obstet Gynecol. 2013 Oct;209(4):345.e1-7
pubmed: 23791840
J Neurochem. 2016 May;137(3):371-83
pubmed: 26896748
Nat Cell Biol. 2007 Oct;9(10):1102-9
pubmed: 17909521
Nat Commun. 2017 May 05;8:15182
pubmed: 28474670
Am J Obstet Gynecol. 2017 Oct;217(4):441.e1-441.e14
pubmed: 28645573
Am J Obstet Gynecol. 2010 Jul;203(1):75.e1-6
pubmed: 20417490
Birth Defects Res C Embryo Today. 2015 Mar;105(1):53-72
pubmed: 25783684
Am J Obstet Gynecol. 2017 Oct;217(4):492-493
pubmed: 28669740
Am J Obstet Gynecol. 2006 Feb;194(2):580-5
pubmed: 16458664
Am J Obstet Gynecol. 2011 Jul;205(1):84.e1-6
pubmed: 21529760
Am J Obstet Gynecol. 2012 May;206(5):448.e1-7
pubmed: 22425406
Am J Obstet Gynecol. 2018 Jul;219(1):113.e1-113.e9
pubmed: 29709511
Diabetes. 2013 Feb;62(2):599-608
pubmed: 22961085
Am J Physiol Endocrinol Metab. 2015 Nov 15;309(10):E861-73
pubmed: 26419589
Am J Obstet Gynecol. 2015 May;212(5):650.e1-11
pubmed: 25595579
Am J Obstet Gynecol. 2015 Aug;213(2):125-34
pubmed: 25595581
Am J Obstet Gynecol. 2016 Feb;214(2):192-202
pubmed: 26432466
Nat Rev Mol Cell Biol. 2007 Jun;8(6):440-50
pubmed: 17522590
Am J Obstet Gynecol. 2018 Feb;218(2S):S745-S761
pubmed: 29422210
Autophagy. 2007 Nov-Dec;3(6):542-5
pubmed: 17611390
Am J Obstet Gynecol. 2005 Mar;192(3):967-72
pubmed: 15746699
Am J Obstet Gynecol. 2015 Jun;212(6):802.e1-8
pubmed: 25595578
Am J Obstet Gynecol. 2017 Aug;217(2):216.e1-216.e13
pubmed: 28412087
Am J Obstet Gynecol. 2008 Jan;198(1):130.e1-7
pubmed: 18166327
J Biol Chem. 2004 Jan 9;279(2):1513-25
pubmed: 14551207
Am J Obstet Gynecol. 2016 Jul;215(1 Suppl):S1-S46
pubmed: 26972897
Am J Obstet Gynecol. 2016 Sep;215(3):368.e1-368.e10
pubmed: 26979632
Am J Obstet Gynecol. 2018 Feb;218(2S):S762-S773
pubmed: 29275823
Am J Obstet Gynecol. 2016 Sep;215(3):366.e1-366.e10
pubmed: 27038779
Am J Obstet Gynecol. 2017 Nov;217(5):592.e1-592.e17
pubmed: 28847437
Am J Obstet Gynecol. 2015 May;212(5):569-79
pubmed: 25434839
Am J Obstet Gynecol. 2008 Sep;199(3):237.e1-9
pubmed: 18674752